Current ENABLE-2 programmes
ENABLE-2 is currently supporting five promising programmes in the pursuit of new antibiotics: One from the University of Strathclyde, one resident at Leiden University and Queen’s University Belfast, one each from biotech companies QureTech Bio AB and Thioredoxin Systems AB, and one programme from Uppsala University.
PROGRAMME BamA Inhibitors
Novel antibiotics that hit a new target against Gram-negative bacteria
Resident at Justus Liebig University Giessen and Fraunhofer IME, Giessen
Till F. Schäberle, PhD, Principal Investigator
Justus Liebig University Giessen
Till.F.Schaeberle@agrar.uni-giessen.de
PROGRAMME GmPcides
A new class of antibacterial compounds against gram-positive bacteria & a well-developed chemistry platform to improve these new compounds.
Resident at QureTech Bio AB, Umeå
Fredrik Almqvist, Research Director
QureTech Bio AB
Fredrik.Almqvist@umu.se
Helén Fält, CEO
QureTech Bio AB
Helen.Falt@quretech.com
PROGRAMME Strathclyde Minor Groove Binders
An anti-infective drug discovery programme with a novel mechanism of action resilient to target-based resistance.
Resident at Department of Pure and Applied Chemistry, University of Strathclyde
Fraser J.Scott, Dr, Senior lecturer
University of Strathclyde
fraser.j.scott@strath.ac.uk
PROGRAMME JEDI
A novel target with no preexisting resistance and a new compound class showing very good efficacy in animal models.
Resident at Drug Design and Discovery, Dep of Medicinal Chemistry & Dep of Medical Biochemistry and Microbiology, Uppsala University
Diarmaid Hughes, Professor
Uppsala University
Diarmaid.Hughes@imbim.uu.se
Anders Karlén, Professor
Uppsala University
Anders.Karlen@ilk.uu.se
PROGRAMME EbsArgent
A novel class of antibiotic active against multidrug-resistant gram-positive as well as gram-negative bacteria.
Resident at Thioredoxin Systems AB, Solna
Elias Arnér, MD PhD, Board Member, Scientific Advisor
Thioredoxin Systems AB
+46 70 556 96 94, ea@txnsystems.com
Mohamad Takwa, PhD, Board Member, CEO
Thioredoxin Systems AB
+46 72-322 22 21, mt@txnsystems.com
PROGRAMME Ornicidine
A novel class of anti-bacterial agents active against multi drug-resistant Gram-negative bacteria.
Resident at Leiden University and Queen’s University Belfast
Nathaniel Martin, Professor
Leiden University
n.i.martin@biology.leidenuniv.nl
Stephen Cochrane, Dr.
Queen’s University Belfast
s.cochrane@qub.ac.uk
CONTACT
Marie Olliver, PhD, Alliance Manager
Uppsala University
Marie.Olliver@ilk.uu.se